Halozyme Therapeutics, Inc. (HALO): Price and Financial Metrics
HALO Price/Volume Stats
Current price | $40.37 | 52-week high | $45.00 |
Prev. close | $40.86 | 52-week low | $29.85 |
Day low | $40.32 | Volume | 1,046,300 |
Day high | $40.96 | Avg. volume | 1,438,836 |
50-day MA | $37.07 | Dividend yield | N/A |
200-day MA | $38.18 | Market Cap | 5.13B |
HALO Stock Price Chart Interactive Chart >
HALO POWR Grades
- HALO scores best on the Value dimension, with a Value rank ahead of 89.68% of US stocks.
- The strongest trend for HALO is in Quality, which has been heading up over the past 26 weeks.
- HALO ranks lowest in Momentum; there it ranks in the 10th percentile.
HALO Stock Summary
- For HALO, its debt to operating expenses ratio is greater than that reported by 82.97% of US equities we're observing.
- HALO's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 92.45% of US stocks.
- As for revenue growth, note that HALO's revenue has grown 34.46% over the past 12 months; that beats the revenue growth of 86.74% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to HALOZYME THERAPEUTICS INC, a group of peers worth examining would be LYFT, ACIW, ZUO, OPGN, and NTAP.
- Visit HALO's SEC page to see the company's official filings. To visit the company's web site, go to www.halozyme.com.
HALO Valuation Summary
- In comparison to the median Healthcare stock, HALO's price/sales ratio is 186.36% higher, now standing at 6.3.
- Over the past 241 months, HALO's price/sales ratio has gone down 133.4.
Below are key valuation metrics over time for HALO.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
HALO | 2023-12-29 | 6.3 | 19.6 | 19.2 | 18.2 |
HALO | 2023-12-28 | 6.3 | 19.7 | 19.3 | 18.2 |
HALO | 2023-12-27 | 6.2 | 19.6 | 19.2 | 18.1 |
HALO | 2023-12-26 | 6.3 | 19.8 | 19.4 | 18.3 |
HALO | 2023-12-22 | 6.3 | 19.7 | 19.3 | 18.2 |
HALO | 2023-12-21 | 6.2 | 19.6 | 19.2 | 18.1 |
HALO Growth Metrics
- The 5 year price growth rate now stands at 79.34%.
- The 5 year net income to common stockholders growth rate now stands at 30.98%.
- The 2 year cash and equivalents growth rate now stands at 12.36%.
The table below shows HALO's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-12-31 | 660.116 | 240.11 | 202.129 |
2022-09-30 | 580.623 | 240.173 | 211.197 |
2022-06-30 | 487.477 | 292.277 | 366.15 |
2022-03-31 | 471.567 | 288.941 | 434.923 |
2021-12-31 | 443.31 | 299.44 | 402.71 |
2021-09-30 | 463.01 | 267.844 | 409.104 |
HALO's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- HALO has a Quality Grade of C, ranking ahead of 73.97% of graded US stocks.
- HALO's asset turnover comes in at 0.493 -- ranking 84th of 682 Pharmaceutical Products stocks.
- ARAV, XOMA, and MGNX are the stocks whose asset turnover ratios are most correlated with HALO.
The table below shows HALO's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-09-30 | 0.493 | 0.814 | 0.250 |
2021-06-30 | 0.533 | 0.823 | 0.255 |
2021-03-31 | 0.510 | 0.832 | 0.224 |
2020-12-31 | 0.504 | 0.838 | 0.220 |
2020-09-30 | 0.378 | 0.831 | 0.053 |
2020-06-30 | 0.369 | 0.720 | -0.037 |
HALO Price Target
For more insight on analysts targets of HALO, see our HALO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $52.82 | Average Broker Recommendation | 1.62 (Moderate Buy) |
Halozyme Therapeutics, Inc. (HALO) Company Bio
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. The company was founded in 1998 and is based in San Diego, California.
Latest HALO News From Around the Web
Below are the latest news stories about HALOZYME THERAPEUTICS INC that investors may wish to consider to help them evaluate HALO as an investment opportunity.
Insider Sell Alert: SVP, Chief Technical Officer Michael Labarre Sells 20,000 Shares of ...Halozyme Therapeutics Inc (NASDAQ:HALO), a biopharmaceutical company known for its novel enzyme technology that targets the extracellular matrix, has recently witnessed a significant insider sell transaction. |
3 Reasons Growth Investors Will Love Halozyme Therapeutics (HALO)Halozyme Therapeutics (HALO) possesses solid growth attributes, which could help it handily outperform the market. |
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-TermWhether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
Why Is Halozyme Therapeutics (HALO) Up 2.8% Since Last Earnings Report?Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Here's Why Halozyme Therapeutics (HALO) is a Strong Value StockWondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
HALO Price Returns
1-mo | 11.83% |
3-mo | 10.97% |
6-mo | 1.15% |
1-year | 15.94% |
3-year | -8.52% |
5-year | 144.67% |
YTD | 9.23% |
2023 | -35.04% |
2022 | 41.51% |
2021 | -5.85% |
2020 | 140.89% |
2019 | 21.19% |
Continue Researching HALO
Want to see what other sources are saying about Halozyme Therapeutics Inc's financials and stock price? Try the links below:Halozyme Therapeutics Inc (HALO) Stock Price | Nasdaq
Halozyme Therapeutics Inc (HALO) Stock Quote, History and News - Yahoo Finance
Halozyme Therapeutics Inc (HALO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...